Rektum Kanserinde Mandard Tümör Regresyon Skorunun Prognostik Değeri: Neoadjuvan Tedavi Sonrası Histopatolojik Parametreler ve Sağkalım ile İlişkisi

Yıl 2025, Cilt: 47 Sayı: 6, 975 - 981, 26.09.2025

Ömer Atmış , Hanife Seda Mavili

https://doi.org/10.20515/otd.1752698

Öz

Rektum kanserinde neoadjuvan kemoradyoterapi sonrası tümör yanıtının değerlendirilmesi, tedavi başarısı, prognoz ve adjuvan tedavi kararlarının belirlenmesinde temel rol oynar. Mandard tümör regresyon skoru (TRG), bu süreçte yaygın olarak kullanılan histopatolojik bir değerlendirme yöntemidir. Bu çalışmada Mandard TRG’nin, histopatolojik parametrelerle ilişkisi ve sağkalım üzerindeki prognostik değeri araştırılmıştır. 2020–2025 yılları arasında neoadjuvan tedavi sonrası cerrahi uygulanan 60 rektum kanseri hastasının verileri retrospektif olarak incelenmiştir. TRG üçlü sınıflama ile (TRG 1: tam yanıt, TRG 2: kısmi yanıt, TRG 3: yanıtsız) değerlendirilmiş; cerrahi sınır durumu, lenfovasküler invazyon, perinöral invazyon, lenf nodu durumu ve sağkalım süresi ile ilişkisi analiz edilmiştir. TRG 3 grubunda mortalite oranı anlamlı şekilde yüksek bulunmuş (p=0,008) ve bu grup; lenfovasküler invazyon, perinöral invazyon, pozitif cerrahi sınır ve ileri evre tümör ile anlamlı ilişki göstermiştir. Kaplan-Meier analizinde yanıtlı gruptaki (TRG 1-2) hastaların ortalama sağkalım süresi belirgin şekilde daha uzun saptanmıştır (56,7 ay vs. 36,1 ay; p=0,010). Çok değişkenli analizde, TRG ile belirlenen yanıt durumu sağkalımı etkileyen sınırda anlamlı tek değişken olarak saptanmıştır (p=0,057). Mandard TRG, neoadjuvan tedavi sonrası rektal kanser hastalarında yalnızca tedavi yanıtını değil, aynı zamanda sağkalımı öngörebilen prognostik bir araçtır. TRG’nin adjuvan tedavi kararları ve takip stratejilerinde yönlendirici olarak kullanımı, kişiselleştirilmiş onkolojik yaklaşım için önemli katkılar sağlayabilir.

Anahtar Kelimeler

rektum kanseri , Mandard tümör regresyon skoru , neoadjuvan tedavi , sağkalım

Prognostic Value of Mandard Tumor Regression Grade in Rectal Cancer: Association with Histopathological Parameters and Survival Following Neoadjuvant Therapy

Öz

In rectal cancer, the evaluation of tumor response after neoadjuvant chemoradiotherapy (nCRT) plays a fundamental role in determining treatment success, prognosis, and decisions regarding adjuvant therapy. The Mandard tumor regression grade (TRG) is a widely used histopathological method for assessing treatment response in this context. This study aimed to investigate the prognostic value of Mandard TRG by analyzing its relationship with histopathological parameters and overall survival. Data from 60 rectal cancer patients who underwent surgery following neoadjuvant therapy between 2020 and 2025 were retrospectively analyzed. TRG was assessed using a three-tier classification (TRG 1: complete response, TRG 2: partial response, TRG 3: no response). Associations between TRG and surgical margin status, lymphovascular invasion, perineural invasion, lymph node status, and survival duration were evaluated. The mortality rate was significantly higher in the TRG 3 group (p=0.008), which also showed significant associations with lymphovascular invasion, perineural invasion, positive surgical margins, and advanced tumor stage. According to Kaplan-Meier analysis, patients in the responder group (TRG 1–2) had a significantly longer average survival time (56.7 months vs. 36.1 months; p=0.010). In multivariate analysis, TRG-based response status was identified as the only variable with borderline statistical significance affecting survival (p=0.057). Mandard TRG is a prognostic tool that reflects not only treatment response but also overall survival in rectal cancer patients following neoadjuvant therapy. Its incorporation into adjuvant treatment decisions and follow-up strategies may contribute significantly to personalized oncologic care.

Anahtar Kelimeler

rectal cancer , Mandard tumor regression grade , neoadjuvant therapy , survival

Kaynakça

• 1. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad gastroenterologiczny. 2019;14(2):89-103.
• 2. Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Translational oncology. 2021;14(10):101174.
• 3. Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(28):3355-75.
• 4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. The New England journal of medicine. 2004;351(17):1731-40.
• 5. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680-6.
• 6. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141-6.
• 7. Tsagkalidis V, Blaszczyk MB. Interpretation of Tumor Response Grade following Preoperative Therapy for Gastric Cancer: An Overview. 2023;15(14).
• 8. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(34):8688-96.
• 9. Dhadda AS, Dickinson P, Zaitoun AM, Gandhi N, Bessell EM. Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. European journal of cancer (Oxford, England : 1990). 2011;47(8):1138-45.
• 10. Kim CH, Yeom SS, Lee SY, Kim HR, Kim YJ, Lee KH, et al. Prognostic Impact of Perineural Invasion in Rectal Cancer After Neoadjuvant Chemoradiotherapy. World journal of surgery. 2019;43(1):260-72.
• 11. Bunjo Z, Sammour T. The Landmark Series: Neoadjuvant Therapy for Locally Advanced Rectal Cancer. Annals of surgical oncology. 2025;32(7):4935-44.
• 12. Li YH, Li JL, Zhu XG, He JY, Lin LM, Lin XY, et al. Associations of tumor regression grade with outcomes in patients with locally advanced rectal cancer treated with preoperative two-week course of radiotherapy. Oncotarget. 2017;8(59):100165-75.
• 13. Mendoza-Moreno F, Díez-Alonso M, Matías-García B, Ovejero-Merino E, Vera-Mansilla C, Quiroga-Valcárcel A, et al. Effect of Tumor Regression Grade on Survival and Disease-Free Interval in Patients Operated on for Locally Advanced Rectal Cancer. Cancers. 2024;16(10):1797.
• 14. Sun Q, Liu T, Liu P, Luo J, Zhang N, Lu K, et al. Perineural and lymphovascular invasion predicts for poor prognosis in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery. Journal of Cancer. 2019;10(10):2243-9.
• 15. Rosa C, Di Tommaso M, Caravatta L, Taraborrelli M, Gasparini L, Di Guglielmo FC, et al. Clinical outcomes in elderly rectal cancer patients treated with neoadjuvant chemoradiotherapy: impact of tumor regression grade. Journal of Cancer Research and Clinical Oncology. 2021;147(4):1179-88.
• 16. Mancini R, Pattaro G, Diodoro MG, Sperduti I, Garufi C, Stigliano V, et al. Tumor Regression Grade After Neoadjuvant Chemoradiation and Surgery for Low Rectal Cancer Evaluated by Multiple Correspondence Analysis: Ten Years as Minimum Follow-up. Clinical Colorectal Cancer. 2018;17(1):e13-e9.
• 17. Laohawiriyakamol S, Chaochankit W, Wanichsuwan W, Kanjanapradit K, Laohawiriyakamol T. An investigation into tumor regression grade as a parameter for locally advanced rectal cancer and 5-year overall survival rate. Ann Coloproctol. 2023;39(1):59-70.